HTR1A and Cognitive impairment: Future antipsychotics may therefore be identified that possess an optimized dual D2/5-HT1A mechanism which retains efficacy against positive symptoms via D2 antagonism, whilst improving cognitive impairment and negative symptoms associated with schizophrenia and functional outcome by activation of 5-HT1A receptors26,27.